Category: Epidarex Portfolio News
Leeds, UK, 25 November 2020: LUNAC Therapeutics Ltd (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants with minimal risk of bleeding, announces that it has appointed Carl Sterritt as Chief Executive Officer. Carl has over 25 years of…
Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate the standard of care in paroxysmal nocturnal hemoglobinuria (PNH) New analyses from the Phase 3 PEGASUS head-to-head study demonstrate greater treatment response and quality–of–life improvements with pegcetacoplan versus eculizumab, a C5 inhibitor Using a matching-adjusted indirect comparison (MAIC), improvements in clinical, hematological and…
Second significant value realisation this quarter highlights Epidarex’s successful approach to life science investing Bethesda, MD, USA, and Edinburgh, UK; November 3rd, 2020 – Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, is pleased to announce its second value realisation this quarter with the…
Co-led by new investors, Vesalius BioCapital III and BioMedPartners, with participation from all existing investors Funds to be used to advance innovative pipeline based on Topas Particle Conjugates technology platform Lead program TPM203 in clinical development for pemphigus vulgaris Second program, TPM501, progressing towards clinic…
Highly accomplished biotech executive with nearly two decades of industry leadership experience Topas is advancing its pipeline based on its Topas Particle Conjugates technology platform, with lead program TPM203 in clinical development for treatment of pemphigus vulgaris and second program, TPM501, progressing towards clinic for…
Enterprise Therapeutics’ first-in-class TMEM16A potentiator program is a novel therapeutic approach applicable to all cystic fibrosis patients, independent of CFTR genotype, and may provide benefit in other respiratory diseases Epidarex Capital was the founding investor in Enterprise Therapeutics in 2015 and was instrumental in setting…
Post hoc analysis of Phase 2 FILLY study shows 39% reduction in rate of progression from nascent GA, an earlier form of disease, to GA in patients treated with pegcetacoplan monthly vs. sham First ever observation of slowed nascent GA progression in a Phase 2 study signals potential benefit of earlier intervention with pegcetacoplan in patients with GA Data support hypothesis that targeting C3 with pegcetacoplan addresses an underlying cause of disease,…
Libra Therapeutics is developing novel therapeutics for neurodegenerative diseases BETHESDA, MD (US) and EDINBURGH (UK), September 23, 2020 – Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, announces it has co-led the $29 Million Series A financing of Libra Therapeutics, Inc. together with Boehringer…